Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Starlight who wrote (544)	1/18/2000 5:15:00 PM
From: OldAIMGuy	Respond to of 1154

Hi Betty, Yes, nice move today with good volume. I haven't found any news to give a clue about the move. I'm not a subscriber either. Best regards, Tom

To: Starlight who wrote (544)	1/18/2000 5:51:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 1154

Re. Street.com mention of GENE. The only thing I found was in the TA section, here are some relevant paragraphs (hope this does not annoy the copyright police. FWIW, the writer, Helene Meisler, is one of the most lucid, if not the only one, chart readers I have come across): Finally we come to the group of charts that have just emerged from long-term bases. Almost all of them have reached their first target prices and should spend some time digesting their gains. This group includes Emisphere Technologies (EMIS:Nasdaq - news), ViroPharma (VPHM:Nasdaq - news), Immunomedics (IMMU:Nasdaq - news), Genome Therapeutics (GENE:Nasdaq - news) and Cell Genesys (CEGE:Nasdaq - news). ... As a reminder, I hardly know what any of these companies do, let alone their financial situation. It is best for you to do your own homework when it comes to making your investment decisions. This list is simply meant as a place to start. That's it. PB [a subscriber of TSC but not a holder of GENE :( ]

To: Starlight who wrote (544)	1/18/2000 8:48:00 PM
From: Richaaard	Read Replies (1) \| Respond to of 1154

I don't think it was any one event that moved the stock. If you look at GENE in relationship to others in the group it was cheap. My opinion right along is that investors are buying the bioinformatic/gene group and that whichever looks cheapest relative to rank, earnings, news, etc, will get the attention. I even attempted to buy more this morning because the disparity between GENE and the others had become obvious IMO. As usual, a day late and a dollar short.